| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2484903 | Journal of Pharmaceutical Sciences | 2012 | 14 Pages |
Abstract
Primary human hepatocytes are widely used for metabolic stability evaluations. However, there are limited data directly comparing phase I and phase II drugâmetabolizing enzymes in fresh and cryopreserved hepatocytes prepared from the same human donor liver. We evaluated the metabolic competency of human hepatocytes prepared from seven donor tissues before and after cryopreservation. Temporalâdependent enzyme activity in suspension and matched adherent cultures of primary human hepatocytes was also assessed. Cryopreservation of hepatocytes resulted in statistically significant increases in activities of CYP1A2, CYP2B6, CYP2C9, CYP2D6, and CYP3A but not CYP2C8, CYP2C19, FMO, UGT, and SULT, relative to fresh hepatocytes. In suspension cultures of hepatocytes, enzyme stabilities were as follows: UGT
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Cornelia M. Smith, Christina K. Nolan, Manda A. Edwards, Jean B. Hatfield, Todd W. Stewart, Stephen S. Ferguson, Edward L. Lecluyse, Jasminder Sahi,
